Natco Pharma share price
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Natco Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Dec 1995 on NSE
Last close ₹787.55down ₹5.45 (0.69%)BSE ₹787.75
Share price at the NSE close on 29 Oct 2026. Previous close ₹793.00.
29 Oct: open ₹793.00, high ₹799.45, low ₹785.90
52-week range of traded prices to 29 Oct 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
- Next results date: the board meets on 13 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,449 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,27,66353.4% delivered
About Natco Pharma
Natco Pharma is a Hyderabad-based drug maker that develops, manufactures and sells finished medicines, active pharmaceutical ingredients (APIs, the chemical substances that make a medicine work) and crop protection products.1 It concentrates on niche and complex generic medicines in cancer, heart, diabetes and other specialty treatments.23 Its customers include distributors, hospitals, government agencies and other drug companies, and its largest markets are the US, India, Canada and Brazil.45
Natco reports 2 segments, pharmaceuticals and agrochemicals; pharmaceuticals bring in most of the revenue, led by export formulations (finished medicines sold abroad), then domestic formulations and APIs.67 In India it sells through 4 divisions: oncology, pharma specialty, cardiology and diabetology.7 Its brands include Veenat (imatinib) for leukaemia and Velpanat (sofosbuvir) for hepatitis C.85 Its crop business sells chlorantraniliprole insecticides and the fungicide Glanz.910 Abroad it works through subsidiaries in the US, Canada, Brazil, Singapore, Indonesia and the Philippines, and through Adcock Ingram, a South African drug maker it holds as an associate (a company it part-owns and influences but does not control).111213
Natco was incorporated in Hyderabad in 1981 and listed on NSE and BSE in 1992; in 2021 it acquired Dash Pharmaceuticals, now NATCO Pharma USA LLC.814 It has a team of more than 5,200 people.15 V.C. Nannapaneni is chairman and managing director, and Rajeev Nannapaneni is vice chairman and chief executive officer.16
Natco Pharma key points
Results
- In the year to Mar 2026, consolidated total revenue was ₹43,759 million (₹47,840 million a year earlier), EBITDA (earnings before interest, tax, depreciation and amortisation) ₹17,341 million (₹25,505 million) and profit after tax, including its share of associate profit, ₹14,185 million (₹18,834 million).17
- In the quarter to Jun 2026, consolidated total revenue fell to ₹794.4 crore from ₹1,390.6 crore a year earlier, mainly on lower lenalidomide (generic Revlimid) sales; EBITDA including other income was ₹245.7 crore.18
- Consolidated profit after tax was ₹206.5 crore in the quarter to Jun 2026, including Natco's ₹84.3 crore share of Adcock Ingram's profit, against ₹269 crore in the quarter to Mar 2026, which included a one-time tax benefit of ₹115 crore.19
Market position
- Natco ranks among the top 10 generic companies by sales in Canada (year to Dec 2025) and says it has the highest market share there in lenalidomide and oseltamivir.2021
- In India, Natco says it is among the top 3 companies in its oncology segment and that more than 20 of its brands rank first in prescriptions for their use.2223
- Natco says it is the first Indian generic maker to launch semaglutide injection for type 2 diabetes.24
Revenue mix
- Sales by business2526
Item year to Mar 2026 year to Mar 2025 Export formulations ₹32,345 million – Domestic formulations ₹4,409 million – Active pharmaceutical ingredients ₹2,347 million – Crop Health Sciences ₹1,382 million ₹606 million - In the quarter to Jun 2026, domestic formulations revenue was ₹136 crore and Brazil revenue ₹178 crore, which the company called a growth of 180%.27
Plants and capacity
- Natco has 9 plants in India: 5 for finished medicines (Kothur, Nagarjuna Sagar, Visakhapatnam, Dehradun, Guwahati), 2 for APIs (Mekaguda, Chennai) and 2 crop protection units at Athivaram.2829
- Capacity added in the year to Mar 202630
Item year to Mar 2026 Nagarjuna Sagar, cancer injectables 10 lakh freeze-dried and 39 lakh liquid vials a year Kothur, granulation line 250 million tablets a year Visakhapatnam, liquid capsule line 75 lakh capsules a year
Research and development
- At the end of Mar 2026 Natco had 28 US Para IV filings (challenges to a branded drug's patents), over 20 of them first-to-file (first generic applicant), including sole filings against Kyprolis, Imbruvica, Lynparza, Ozempic and Wegovy.31
- Its own cancer molecule NRC-2694-A is in a US FDA-approved phase 2 (mid-stage) trial for recurrent or metastatic head and neck cancer, enrolling patients in the US and India.32
- On 25 Aug 2026 the company said it is investing US$14 million more in eGenesis, which develops genetically engineered pig organs for transplant, taking its total to US$22 million.33
Stake in Adcock Ingram
- On 14 Jul 2026 Natco completed buying a further 13.25% of Adcock Ingram for about ZAR 1.81 billion (around ₹1,060 crore), raising its holding from 35.75% to 49%.34
- Natco first reached 35.75% in November 2025, paying about ZAR 4.0 billion for 34.88% as Adcock Ingram delisted from the Johannesburg Stock Exchange.35
- Natco says Adcock Ingram is South Africa's second-largest drug company by private market share, holding 10% of that market; its brands include Panado, Allergex and Citro-Soda.3637
- Adcock Ingram reported revenue of US$592 million and profit after tax of US$57 million in its year to Jun 2026.38
What the company expects
- The company stated in its annual report for the year to Mar 2026 that it expects double-digit earnings growth over the next 2 to 3 years.39
- On its earnings call of 14 Aug 2026, the company said it expects domestic volumes to rise about 25% in the year to Mar 2027 and its crop health business to break even for the year.4041
- On its earnings call of 14 Aug 2026, the company said its capital spending runs at about ₹250 crore to ₹300 crore a year and is weighing 2 acquisitions, for which it wants to raise funds.4243
- On its earnings call of 14 Aug 2026, the company said it has 2 US launches in the year to Mar 2028 and intends to launch with exclusivity (sole generic seller for a period).44
Recent events
- On 21 Sep 2026 Natco received in-principle approval from NSE and BSE for a rights issue (new shares offered to existing shareholders).45
- The US FDA inspected the Visakhapatnam formulation plant from 17 to 21 Aug 2026 and issued a Form 483 (a list of inspectors' observations) with 4 observations.46
- On 18 Jul 2026 the US FDA gave tentative approval (pending patent issues) to Natco's olaparib tablets, a generic of Lynparza; the Para IV patent case was then ongoing.47
- On 24 Mar 2026 the board approved demerging (splitting off) the agrochemicals business into subsidiary Natco Crop Health Sciences Limited; at its annual report of 4 Sep 2026 the scheme still awaited shareholder, exchange, SEBI and National Company Law Tribunal approval.48
Last updated
All 48 sources, each with its page
- 1. Exchange filing, 18 Jul 2026, page 2
- 2. Annual report, 4 Sep 2026, page 60
- 3. Annual report, 4 Sep 2026, page 13
- 4. Annual report, 4 Sep 2026, page 107
- 5. Annual report, 4 Sep 2026, page 61
- 6. Annual report, 4 Sep 2026, page 65
- 7. Annual report, 4 Sep 2026, page 61
- 8. Annual report, 4 Sep 2026, page 8
- 9. Investor presentation, 19 Aug 2026, page 11
- 10. Investor presentation, 19 Aug 2026, page 20
- 11. Annual report, 4 Sep 2026, page 28
- 12. Annual report, 4 Sep 2026, page 9
- 13. Exchange filing, 14 Jul 2026, page 3
- 14. Investor presentation, 19 Aug 2026, page 7
- 15. Annual report, 4 Sep 2026, page 10
- 16. Annual report, 4 Sep 2026, page 11
- 17. Annual report, 4 Sep 2026, page 63
- 18. Earnings call, 14 Aug 2026, page 3
- 19. Earnings call, 14 Aug 2026, page 4
- 20. Investor presentation, 19 Aug 2026, page 6
- 21. Investor presentation, 19 Aug 2026, page 15
- 22. Investor presentation, 19 Aug 2026, page 14
- 23. Investor presentation, 19 Aug 2026, page 11
- 24. Annual report, 4 Sep 2026, page 61
- 25. Investor presentation, 19 Aug 2026, page 11
- 26. Annual report, 4 Sep 2026, page 10
- 27. Earnings call, 14 Aug 2026, page 4
- 28. Annual report, 4 Sep 2026, page 60
- 29. Investor presentation, 19 Aug 2026, page 17
- 30. Annual report, 4 Sep 2026, page 29
- 31. Investor presentation, 19 Aug 2026, page 13
- 32. Investor presentation, 19 Aug 2026, page 19
- 33. Exchange filing, 25 Aug 2026, page 2
- 34. Exchange filing, 14 Jul 2026, page 2
- 35. Annual report, 4 Sep 2026, page 6
- 36. Exchange filing, 14 Jul 2026, page 3
- 37. Annual report, 4 Sep 2026, page 6
- 38. Annual report, 4 Sep 2026, page 10
- 39. Annual report, 4 Sep 2026, page 11
- 40. Earnings call, 14 Aug 2026, page 5
- 41. Earnings call, 14 Aug 2026, page 7
- 42. Earnings call, 14 Aug 2026, page 11
- 43. Earnings call, 14 Aug 2026, page 14
- 44. Earnings call, 14 Aug 2026, page 15
- 45. Exchange filing, 21 Sep 2026, page 1
- 46. Exchange filing, 21 Aug 2026, page 2
- 47. Exchange filing, 18 Jul 2026, page 2
- 48. Annual report, 4 Sep 2026, page 79
Results
Consolidated; ₹ crore.Natco Pharma quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −20.7%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −32.6%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹735 Crdown 0.53%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹207 Crdown 23.23%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 28.1%
Revenue by quarter
Peak revenue ₹1,371 Cr, quarter to Sep 2024; lowest ₹475 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 |
| Net profit | 677 | 132 | 406 | 480 | 518 | 151 | 269 | 207 |
| Net margin | 49.3% | 27.9% | 33.3% | 36.1% | 38.0% | 23.4% | 36.4% | 28.1% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹4,078 Crdown 7.93%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,419 Crdown 24.68%
- Net margin
- 34.8%
Revenue by year
Peak revenue ₹4,430 Cr, year to Mar 2025; lowest ₹1,915 Cr, year to Mar 2020
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,065 | 2,202what Revenue, Mar 2018, includes. This period's revenue includes excise duty of ₹17 crore, a tax on the goods the company makes that it collects and pays to the government. | 2,095 | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 | 4,430 | 4,078 |
| Net profit | 486 | 695 | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,883 | 1,419 |
| Net margin | 23.5% | 31.6% | 30.7% | 23.9% | 21.6% | 8.7% | 26.4% | 34.7% | 42.5% | 34.8% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- PharmaceuticalsPharmaceuticals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹3,940 Crdown 9.81%96.6%
- Agro chemicalsAgro chemicals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹138 Crup 128.05%3.4%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Not shown, P/B: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned.Natco Pharma PE ratio and valuation
Price to earnings
At or below today's level on 24% of 2,479 trading days over the last 10 years.
LowestHighest
Its median21.14Industry median28.38
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 22% of 2,479 trading days over the last 10 years.
LowestHighest
Its median0.78%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +22.5% | −24.8% | +62.1% | 0.5% |
| 3 years | +20.8% | +26.4% | −5.1% | 0.8% |
| 5 years | +4.1% | +26.8% | −18.5% | 0.8% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
83 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 63 of the 66 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 83 funds holding Natco Pharma
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 26
- CutCut. Funds that held fewer shares than at the end of the month before.
- 40
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 13
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 2
| Fund | |||
|---|---|---|---|
 Tata Small Cap FundTata Mutual Fund | 8,28,616 | 0.52% | ₹68.6 Cr |
| Tata Value FundTata Mutual Fund | 7,00,001 | 0.70% | ₹57.9 Cr |
 Sundaram Small Cap FundSundaram Mutual Fund | 5,51,707 | 1.11% | ₹45.7 Cr |
| Tata India Pharma & Healthcare FundTata Mutual Fund | 2,75,137 | 1.51% | ₹22.8 Cr |
 Bandhan Multi Cap FundBandhan Mutual Fund | 2,75,000 | 0.77% | ₹22.8 Cr |
 quant Healthcare Fundquant Mutual Fund | 1,54,500 | 3.01% | ₹12.8 Cr |
 Nippon India Nifty Smallcap 250 Index FundNippon India Mutual Fund | 1,38,942 | 0.33% | ₹11.5 Cr |
 Aditya Birla Sun Life Pharma and Healthcare FundAditya Birla Sun Life Mutual Fund | 1,20,000 | 0.92% | ₹9.93 Cr |
 HDFC Nifty Smallcap 250 ETFHDFC Mutual Fund | 1,09,023 | 0.33% | ₹9.02 Cr |
 Axis Nifty Smallcap 50 Index FundAxis Mutual Fund | 82,108 | 0.87% | ₹6.79 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Natco Pharma insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group1 purchase, 5 sales₹0.85 Cr₹17 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹17 Cr1 pledge created · 16 off-market moves
- Others: no market trade · 1 pledge filing of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Natco Pharma competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Natco Pharma in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Alivus Life SciencesALIVUS | 17,156 | 25.62 | 4.72 | +8.2% | +26.3% | 20.2% | 23.1% | 0.36% |
 Eris LifesciencesERIS | 16,144 | 22.81 | 3.90 | +11.1% | +70.2% | 19.6% | 13.4% | 0.62% |
 AstraZeneca Pharma IndiaASTRAZEN | 15,748 | 92.84 | 18.04 | +31.1% | −7.5% | 20.6% | 24.4% | 0.57% |
 Alembic PharmaceuticalsAPLLTD | 15,624 | 22.61 | 2.75 | +14.1% | +14.6% | 12.7% | 11.8% | 1.51% |
 Jubilant PharmovaJUBLPHARMA | 15,068 | 42.79 | 2.12 | +16.3% | −23.5% | 5.3% | 7.3% | 0.53% |
 Marksans PharmaMARKSANS | 14,291 | 27.65 | 4.73 | – | – | 17.1% | 19.9% | 0.29% |
 CORONA RemediesCORONA | 13,562 | 68.14 | 18.16 | – | – | 26.6% | 30.9% | 0.45% |
 Concord BiotechCONCORDBIO | 12,874 | 45.58 | 6.20 | +4.0% | −12.8% | 14.5% | 15.9% | 0.61% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Natco Pharma dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹9.50 a share, year to Mar 2024.
| Ex-date | Type | Per share |
|---|---|---|
| 20 Aug 2026 | Interim | ₹1.50 |
| 18 Feb 2026 | Interim | ₹1.50 |
| 20 Nov 2025 | Interim | ₹1.50 |
| 19 Aug 2025 | Interim | ₹2.00 |
| 18 Feb 2025 | Interim | ₹1.50 |
| 27 Nov 2024 | Interim | ₹1.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Natco Pharma announcements
Oct 2026
Sep 2026
Natco Pharma share price by year
Each calendar year to 2025.Natco Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 903.05 | −34.9% | 1,397.30 | 746.50 |
| 2024 | 1,387.30 | +71.0% | 1,592.85 | 818.30 |
| 2023 | 811.35 | +44.5% | 914.25 | 523.90 |
| 2022 | 561.65 | −37.9% | 927.75 | 549.35 |
| 2021 | 904.65 | −6.0% | 1,162.05 | 790.40 |
| 2020 | 961.95 | +62.1% | 971.40 | 465.75 |
| 2019 | 593.45 | −12.7% | 703.40 | 502.65 |
| 2018 | 680.05 | −29.3% | 1,035.70 | 655.20 |
| 2017 | 961.70 | +65.9% | 1,077.45 | 583.30 |
| 2016 | 579.65 | +0.1% | 688.90 | 393.10 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 785.00 | 802.00 | 779.05 | 793.00 | 789.31 | 8,43,955 | 57.8% |
| 27 Oct 2026 | 785.50 | 798.85 | 785.50 | 794.55 | 791.12 | 4,33,459 | 62.5% |
| 26 Oct 2026 | 788.30 | 796.05 | 782.60 | 790.20 | 787.59 | 4,05,226 | 61.9% |
| 23 Oct 2026 | 785.00 | 797.45 | 778.00 | 791.85 | 785.85 | 5,69,535 | 50.8% |
| 22 Oct 2026 | 780.00 | 789.00 | 773.60 | 785.15 | 783.49 | 6,99,649 | 63.9% |
| 21 Oct 2026 | 799.00 | 800.65 | 780.00 | 784.45 | 784.68 | 4,80,152 | 51.2% |
| 19 Oct 2026 | 785.05 | 809.80 | 779.50 | 800.85 | 799.60 | 7,68,065 | 26.9% |
| 16 Oct 2026 | 786.95 | 788.50 | 780.95 | 785.05 | 785.74 | 4,97,871 | 73.4% |
| 15 Oct 2026 | 784.00 | 787.60 | 779.00 | 784.95 | 784.05 | 2,97,976 | 65.1% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 1 Oct 2026 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 26 Nov 2015 | Split | 0.2000 | Each share became 5. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- NATCOPHARM
- BSE code
- 524816
- ISIN
- INE987B01026
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.natcopharma.co.in
- CIN
- L24230TG1981PLC003201
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1981
- Registered office
- Natco House, Road No 2, Banjara Hills, Hyderabad 500033, Telangana
- Share registrar
- Venture Capital & Corporate Investments Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, Nifty Smallcap 100, BSE SmallCap